Lipoprotein (a): A risk factor for atherosclerosis: Importance in clinical practice;La lipoproteine (a), un facteur de risque cardio-vasculaire: Interet de sa determination en pratique courante

Journal des Maladies Vasculaires

Volumn 23, Issue 3, 1998, Pages 165-175

  Couderc, R ^a   Maachi, M ^a  

^a HÔPITAL TENON   (France)

Author keywords

Atherosclerosis; Epidemiology; Lp(a); Risk factors for cardio or cerebrovascular disease

Indexed keywords

LIPOPROTEIN A;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; THROMBOGENESIS; ARTERIOSCLEROSIS; BLOOD; CHEMISTRY; DIABETIC ANGIOPATHY; FEMALE; HUMAN; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; STRUCTURE ACTIVITY RELATION;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; LIPOPROTEIN(A); RENAL DIALYSIS; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032084249     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. ABE A, NOMA A, LEE YJ, YAMAGUCHI H. Studies on apolipoprotein (a) phenotypes. Part 2. Phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiographically defined coronary artery diseases. Atherosclerosis, 1992; 96: 9-15.
2. ALFTHAN G, PEKKANEN J, JAUHIAINEN M, PITKANIEMI J, KARVONEN M, TUOMILEHTO J, SALONEN JT, EHNHOLM C. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective finnish population based study. Atherosclerosis, 1994; 106: 9-19.
3. AMEMIYA H, ARINAMI T, KIKUCHI S, YAMAKAWA-KOBAYASHI K, LI L, FUJIWARA H, HIROE M, MARUMO F, HAMAGUCHI H. Apolipoprotein (a) size and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis, 1996; 123: 181-91.
4. AMSTRONG VW, CREMER P, EBERLE E, MANKE A, SCHULZE F, WIELAND H, KREUZER H, SEIDEL D. The association between serum Lp(a) concentration and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis, 1986; 62: 249-57.
5. ARNADOTTIR M, BERG AL, DALLONGEVILLE J, FRUCHART JC, NILSSON-EHLE P. Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients. Kidney Int, 1997; 52: 1651-5.
6. ASSMANN G, SCHULTE H, ECKARDSTEIN AV. Hypertriglyceridemia and elevated Lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol, 1996; 77: 1179-84.
7. BAILLEUL S, COUDERC R, ROSSIGNOL C, FERMANIAN J, BOUTOUCHENT F, FARNIER MA, ETIENNE J. Lipoprotein (a) in childhood: relation with other atherosclerosis risk factors and family history of atherosclerosis. Clin Chem, 1995; 41: 241-5.
8. BIGOT E, ROBERT B, BARD JM, MAINARD F. Lipoprotein (a) phenotype distribution in a population of bypass patients and its influence on lipoprotein (a) concentration. Clin Chim Acta, 1997; 265: 99-111.
9. BOSTOM AG, CUPPLES LA, JENNER JL, ORDOVAS JM, SEMAN LJ, WILSON WF, SCHAEFER EJ, CASTELLI WP. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. JAMA, 1996; 276: 544-8.
10. BOSTOM AG, GAGNON DR, CUPPLES LA, WILSON PWF, JENNER JL, ORDOVAS JM, SCHAEFER EJ, CASTELLI WP. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation, 1994; 90: 1688-95.
11. BOWDEN JF, PRITCHARD PH, HILL JS, FROHLICH JJ. Lp(a) Concentration and apo (a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscl Thromb, 1994; 14: 1561-8.
12. BREWER BH, SCANU A. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In Lipoprotein (a). Ed Academic Press Inc, San Diego, 1990; 211-20.
13. BRUNELLI C, SPALLAROSSA P, BERTOLINI S, BALBI M, BARBARA C, MASTURZO P, LANTIERI P, PASTORINI C, CAPONNETTO S. Lipoprotein (a) is increased in acute coronary syndromes (unstable angina pectoris and myocardial infarction), but it is not predictive of the severity of coronary lesions. Clin Cardiol, 1995; 18: 526-9.
14. CAIXAS A, PEREZ A, ORDONEZ-ILANOS J, BONET R, RIGLA M, CAS TELLVI A, BAYEN L, DE LEIVA A. Lack of change of lipoprotein (a) levels by the optimization of glycemic control with insulin therapy in NIDDM Patients. Diabetes Care, 1997; 20: 1459-61.
15. CANTIN B, MOORJANI S, DESPRES JP, DAGENAIS GR and LUPIEN PJ. Lp(a) in ischemic heart disease. The Québec Cardiovascular Study (abstract). J Am Coll Cardiol, 1994; 23: 482.
16. CARLSON LA, HAMSTEN A, ASPLUND A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med, 1989; 226: 271-6.
17. COLEMAN MP, KEY TI, WANG DY, HERMON C, FENTIMAN IS, ALLEN DS, JARVIS M, PIKE MC, SANDERS TA. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis, 1992; 92: 177-85.
18. CONTOIS JH, LAMMI-KEEFE CJ, VOGEL S, NAMARA JR, WILSON PWF, MASSOV T, SCHAEFER EJ. Plasma lipoprotein (a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay. Clin Chim Acta, 1996; 253: 21-35.
19. CORSETTI JP, STERRY JA, SPARKS JD, SPARKS CE, WEINTRAUB M. Effect of weight loss on serum lipoprotein (a) concentrations in a obese population. Clin Chem, 1991; 37: 1191-5.
20. COUDERC R, BENAMER H, GARBAZ E, JULIARD JM, CHAOUCHE S, BROCHET E, BUATOIS M, FERRÌERE F. Apo (a) phenotypes and Lp(a) levels in acute coronary syndromes. Atherosclerosis, 1997; 134: 138 (abstract).
21. CRAIG WY, LEDUE TB. Lipoprotein (a) and the acute phase response. Clin Chim Acta, 1992; 210: 231-2.
22. CREMER P, NAGEL D, LABROT B, MANN H, MUCHE R, ELSTER H, SEIDEL D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors : results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest, 1994; 24: 444-53.
23. CREMER P, NAGEL D, MANN H, LABROT B, MÜLLER-BERNINGER R, ELSTER H, SCIDEL D. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis, 1997; 129: 221-30.
24. CRESSMAN MD, HEYKA RJ, PAGANINI EP, O'NEIL J, SKIBINSKI CI, HOFF HF. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation, 1992; 86: 475-82.
25. DE BRUIN TWA, VAN BARLINGEN H, VAN LINDESIBENIUS TRIP M, VAN VUURST DE VRIES AR, AKVELD MJ, ERKELENS DW. Lipoprotein (a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J Clin Endocrinol Metab, 1993; 76: 121-6.
26. DESMARAIS RL, SAREMBOCK IJ, AYERS CR, VERNON SM, POWERS ER, GIMPLE LW. Elevated Serum Lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation, 1995; 91: 1403-9.
27. DIEPLINGER H, LACKNER C, KRONENBERG F, SANDHOLZER C, LHOTTA K, HOPPICHIER F, GRAF H, and KÖNIG P. Elevated plasma concentrations of lipoprotein (a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein (a). J Clin Invest, 1993; 91: 397-401.
28. EDWARD D, HARRIS D. Lipoprotein (a): a predictor of atherosclerotic disease. Nutrition reviews, 1997; 55: 61-4.
29. EVANS RW, SANKEY SS, HAUTH BA, SUTTON-TYRRELL K, KAMBOH MI, KULLER LH. Effect of storage on quantitation of lipoprotein (a) by an enzyme-linked immunosorbent assay. Lipids, 1996; 31: 1197-203.
30. FIORINI F, MASTURZO P, Mu M, BERTOLINI S. Lipoprotein (a) levels in hemodialysis patients: relation to glucose intolerance and hemodialysis duration. Nephron, 1995; 70: 500-1.
31. FRIEDLANDER Y, LEITERSDORF E. Segregation analysis of plasma lipoprotein (a) levels in pedigrees with moleculary defined familial hypercholesterolemia. Genetic Epidemiology, 1995; 12: 129-43.
32. HAFFNER SM, MORALES PA, GRUBER MK, HAZUDA HP, STERN MP. Cardiovascular risk factors in non-isulin-dependent diabetic subjects with microalbuminuria. Arterioscl Thromb, 1993; 13: 205-10.
33. HAJJAR KA, GAVISH D, BRESLOW JL, NACHMAN RL. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature, 1989; 339: 303-5.
34. HEARN JA, DEMAIO SJ, ROUBIN GS, HAMMARSTROM M, SGOUTAS D. Predictive values of lipoprotein (a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol, 1990; 66: 1176-80.
35. HIRAGA T, SHIMADA M, OKUBO M, NAKANISHI K, KOBAYASHI T, MURASE T. Lipoprotein (a) is an independent risk factor for multiple cerebral infarctions. Atherosclerosis, 1996; 122: 29-32.
36. HIRATA K, KIKUCHI S, SAKU K, JIMI S, ZHANG B, NAITO S, HAMAGUCHI H, ARAKAWA K. Apolipoprotein (a) phenotypes and serum lipoprotein (a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int, 1993; 44: 1062-70.
37. HOPKINS PN, Wu LL, HUNT SC, JAMES BC, VINCENT GM, WILLIAMS RR. Lipoprotein (a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscl Thromb Vasc Biol, 1997; 17: 2783-92.
38. HUBY T, CHAPMAN J, THILLET J. Pathophysiological implication of the structural domains of lipoprotein (a). Atherosclerosis, 1997; 133: 1-6.
39. JAUHIAINEN M, KOSKINEN P, EHNHOLM C, FRICK MH, MÄNTTÄRI M, MANNINEN V, HUTTUNEN JK. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis, 1991; 89: 59-67.
40. JENKINS AJ, STEELE JS, JANUS ED, BEST JD. Increased plasma apolipoprotein (a) levels in IDDM patients with micro-albuminuria. Diabetes, 1991; 40: 787-90.
41. JOVICIC A, IVANIESEVIC V, IVANOVIC I. Lipoprotein (a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis, 1993; 98: 59-65.
42. JÜRGENS G, TADDEI-PETERS W, KÖLTRINGER P, PETEK W, CHEN Q, GREILBERGER J, MACOMBER PF, BUTMAN BT, STEAD AG, RANSOM JH. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke, 1995; 26: 1841-8.
43. KANNO H, SAITO E, FUJIOKA T, YASUGI T. Lipoprotein (a) levels in the nephrotic syndrome. Internal Med, 1992; 31: 1004-8.
44. KINLAY S, DOBSON AJ, HELLER RF, MCELDUFF P, ALEXANDER H, DICKESON J. Risk of primary and recurrent acute myocardial infarction from lipoprotein(a) in men and women. J Am Coll Cardiol, 1996; 28: 870-5.
45. KLAUSEN C, SJOL A, HANSEN PS, GERDES LU, MOLLER L, LEMMING L, SCHROLL M, FAERGEMAN O. Apolipoprotein (a) isoforms and coronary heart disease in men. A nested case-control study. Atherosclerosis, 1997; 132: 77-84.
46. KLAUSEN IC, BERG K, SCHMIDT E, LERVANG HH, GERDES LU, DITZEL J, FAERGEMAN O. Normal lipoprotein (a) concentrations and apolipoprotein (a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest, 1992; 22: 538-41.
47. KRAFT HG, LINGENHEL A, KÖCHL S, HOPPICHLER F, KRONENBERG F, ABE A, MÜHLBERGER V, SCHÖNITZER D, UTERMANN G. Apolipoprotein (a) Kringle IV repeat number predicts risk, for coronary heart disease. Arterioscl Thromb Vasc Biol, 1996; 16: 713-9.
48. KRONENBERG F, KÖNIG P, NEYER U, AUINGER M, PRIBASNIG A, LANG U, REITINGER J, PINTER G, UTERMANN G, DIEPLINGER H. Multicenter study of lipoprotein (a) and apolipoprotein (a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol, 1995; 6: 110-20.
49. KRONENBERG F, STEINMETZ A, KOSTNER GM, DIEPLINGER H. Lipoprotein (a) in health and disease. Crit Rev Cl Lab Sc, 1996; 33: 495-543.
50. KROON A, DEMACKER P, STALENHOEF A. N-acetylcysteine and serum concentration of lipoprotein (a). J Intern Med, 1991; 230: 519-26.
51. LABEUR C, DE BACQUER D, DE BACKER G, VINCKE J, MUYLDERMANS L, VANDEKERCKHOVE Y, VAN der STICHELE E, ROSSENEU M. Plasma lipoprotein (a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem, 1992; 38: 2261-6.
52. LOSCALZO J, WEINFIELD M, FLESS GM, SCANU AM. Lipoprotein (a) fibrin binding, and plasminogen activation. Arterioscl Thromb, 1990; 10: 240-5.
53. MACA T, AHMADI R, DERFLER K, HÖRL W, KOPPENSTEINER R, MINAR E, SCHNEIDER B, STÜMPFLEN A, EHRINGER H. Elevated lipoprotein (a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Atherosclerosis, 1996; 127: 27-34.
54. MAHER V, BROWN BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol, 1995; 6: 229-35.
55. MARKUS HS, KAPADIA R, SHERWOOD RA. Relationship between lipoprotein (a) and both stroke and carotid atheroma. Am Clin Biochem, 1997; 34: 360-5.
56. MBEWU AD, BHATNAGAR D, DURRINGTON PN, HUNT L, ISHOLA M, ARROL S, MACKNESS M, LOCKLEY P, MILLER JP. Serum lipoprotein (a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscl Thromb, 1991; 11: 940-6.
57. MILES LA, FLESS GM, LEVIN EG, SCANU AM, PLOW EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature, 1989; 339: 301-3.
58. MIYATA M, BIRO S, ARIMA S, HAMASAKI S, KAIEDA H, NAKAO S, KAWATAKI M, NOMOTO K, TANAKA H. High serum concentration of lipoprotein (a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J, 1996; 132: 269-73.
59. MÖLGAARD J, KLAUSEN C, LASSVIK C, FAERGEMAN O, GERDES LU, OLSSON AG. Significant association between low-molecular-weight apolipoprotein (a) isoforms and intermittent claudication. Arterioscl Thromb, 1992; 12: 895-901.
60. OIDA K, HIROTADA T, MAEDA H, TAKAHASHI S, SHIMADA A, SUZUKI J, TAMAI T, NAKAI T, MIYABO S. Apolipoprotein (a) is present in urine and ils excretion is decreased in patients with renal failure. Clin Chem, 1992; 38: 2244-8.
61. PHILLIPS J, ROBERTS G, BOLGER C, EL BAGHDADY A, BOUCHIER-HAYES D, FARRELL M, PATH FRC, COLLINS P. Lipoprotein (a): a potential biological marker for unruptured intracranial aneurysms. Neurosurgery, 1997; 40: 1112-7.
62. RELIMPIO F, PUMAR A, LOSADA F, MONTILLA C, MORALES F, ACOSTA D, ASTORGA R. Lack of association of lipoprotein (a) with coronary heart disease in Spaniard type 2 diabetic patients. Diabetes Res Clin Pr, 1997; 35: 135-41.
63. RHOADS GG, DAHLEN G, BERG K, MORTON NE, DANNENBERG AL. Lp(a) lipoprotein is a risk factor for myocardial infarction. JAMA, 1986; 256: 2540-4.
64. RIDKER PM, HENNEKENS CH, STAMPFER MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA, 1993; 270: 2195-9.
65. ROSENGREN A, WILHELMSEN L, ERIKSSON E, RISBERG B, WEDEL H. Lipoprotein (a) and coronary heart disease : a prospective case-control study in a general population sample of middle aged men. Br Med J, 1990; 301: 1248-51.
66. RYMER J, CROOK D, SIDHU M, CHAPMAN M, STEVENSON JC. Effects of tibolone on serum concentrations of lipoprotein (a) in postmenopausal women. Acta Endocrinol, 1993; 128: 259-62.
67. SALVI A, DI STEPHANO O, SLEIMAN I, SPANDRIO S, BALESTRIERI GP, SCALVINI T. Effects of fish oil on serum lipids and lipoprotein (a) levels in heterozygous familial hypercholesterolemia. Curr Ther Res, 1993; 53: 917-21.
68. SANDHOLZER C, BOERWINKLE E, SAHA N, TONG MC, UTERMANN G. Apolipoprotein (a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a chinese population : evidence for the role of the apo (a) gene in coronary heart disease. J Clin Invest, 1992; 1040-6.
69. SANDKAMP M, FUNLTE H, KOHLER E, ASSMANN G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem, 1990; 36: 20-3.
70. SCANU AM, EDELSTEIN C. Kringle-dependent structural and functional polymorphism of apolipoprotein(a). Biochim Biophys Acta, 1995; 1256: 1-12.
71. SCHAEFER EJ, LAMON-FAVA S, JENNER JL, MCNAMARA J, ORDOVAS JM, DAVIS E, ABOLAFIA JM, LIPPEL K, LEVY RI. Lipoprotein (a) levels and risk of coronary heart disease in men. The lipid research clinics coronary primary prevention trial. JAMA, 1994; 271: 990-1003.
72. SEED M, HOPPICHLER F, REAVELEY D, MCCARTHY S, THOMPSON GR, BOERWINKLE E, UTERMANN G. Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med, 1990; 322: 1494-9.
73. SHAH PK, AMIN J. Low high density lipoprotein levels is associated with increased restenosis rate after coronary angioplasty. Circulation, 1992; 85: 1283-8.
74. SHINTANI S, KIKUCHI S, HAMAGUCHI H, SHIIGAI T. High serum lipoprotein (a) levels are an independent risk factor for cerebral infarction. Stroke, 1993; 24: 965-9.
75. SIGURDSSON G, BALDURSDOTTIR A, SIGVALDASON H, AGNARSSON U, THORGEIRSSON G, SIGFUSSON N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol, 1992; 69: 1251-4.
76. SIMON DI, FLESS GM, SCANU AM, LOSCALZO J. Tissue type plasminogen-activator binds to and is inhibited by surface-bound Lp(a) and LDL. Biochemistry, 1991; 30: 6671-7.
77. SIMONI G, GIANOTTI A, ARDIA A, BAIARDI A and CIVALLERI D. Gemfibrozil and mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol - pilot study. Cardiovasc Drugs Ther, 1995; 9: 347-50.
78. SOMA MR, OSNAGO-GADDA I, PAOLETTI R, FUMAGALLI R, MORRISETT JD, MESCHIA M, CROSIGNANT P. The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med, 1993; 153: 1462-8.
79. SRINIVASAN SR, DAHLEN GH, JARPA RA, WEBBER LS, BERENSON GS. Racial (Black-White) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation, 1991; 84: 160-7.
80. STUBBS P, SEED M, MOSELEY D, O'CONNOR B, COLLINSON P, NOBLE M. A prospective study of the role of lipoprotein (a) in the pathogenesis of unstable angina. Eur Heart J, 1997; 18: 603-7.
81. SUNAYAMA S, DAIDA H, MOKUNO H, MIYANO H, YOKOI H, LEE YJ, SAKURAI H, YMAMGUCHI H. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein (a) in women ≥ 55 years of age. Circulation, 1996; 94: 1263-8.
82. UTERMANN G. The mysteries of lipoprotein (a). Science, 1989; 246: 904-10.
83. WADE DP, CLARKE JG, LINDAHL GE, LIU AC, ZYSOW BR, MEER K, SCHWARTZ K, LAUW RM. Genetic influences on lipoprotein (a) concentration. Biochem Soc Trans, 1993; 21: 499-502.
84. WALD NJ, LAW M, WATT HC, WU T, BAILEY A, JOHNSON AM, CRAIG WY, LEDUE TB, HADDOW JE. Apolipoproteins and ischaemic heart disease : implications for screening. Lancet, 1994; 343: 75-9.
85. WANG XL, TAM C, MCCREDIE RM, WILCKEN DEL. Determinants of severity of coronary artery disease in australian men and women. Circulation, 1994; 89: 1974-81.
86. WEBSTER JM, STEWART M, AL-MASKARI M, OSMAN I, KENDALL-TAYLOR P, MITCHESON J, LAKER MF. The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein (a) in growth hormone-deficient adults. Atherosclerosis, 1997; 133: 115-21.
87. WILD SH, FORTMANN SP, MARCOVINA SM. A prospective case-control study of lipoprotein (a) levels and apo (a) size and risk of coronary heart disease in Stanford five-city project participants. Arterioscler Thromb Vasc Biol, 1997; 17: 239-45.
88. WILKLUND O, ANGELIN B, OLOFSSON SO, ERIKSSON M, FAGER G, BERGLUND L, BONDJERS G. Apolipoprotein (a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet, 1990; 335: 1360-3.
89. Wu JH, KAO JT, WEN MS, Wu D. Coronary artery disease risk predicted by plasma concentrations of high-density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein (a) in a general chinese population. Clin Chem, 1993; 39: 209-12.
90. YAMAMOTO H, IMAZU M, YAMABE T, UEDA H, HATTORI Y, YAMAKIDO M. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein (a). Am Heart J. 1995; 130: 1168-73.
91. YAMAMOTO M, EGUSA G, YAMAKIDO M. Carotid atherosclerosis and serum lipoprotein (a) concentrations in patients with NIDDM. Diabetes Care, 1997; 20: 829-31.
92. YIGITOGLU MR, POLAT MF, AKÇAY F, ARI Z, UYANIK BS, OZILGILI HM. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis. Jpn Heart J, 1997; 38: 83-9.
93. ZIONCHECK TF, POWELL LM, RICE GC, EATON DL, LAWN RM. Interaction of recombinant apolipoprotein (a) and lipoprotein (a) with macrophages. J Clin Invest, 1991; 87: 767-71.